YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
(RTTNews) - Nkarta, Inc., (NKTX) a clinical-stage biotech company, posted its second quarter financial results, reflecting a wider net loss compared with the prior-year quarter, primarily attributed to higher operating expenses and lower o…
Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Alyssa Levin appointed to Board of Directors and as Chair of the Audit CommitteeClara Cambon-Thiebaud joins as VP, Regulatory AffairsCéline Breda joins as VP, Chemistry, M…
SOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced i…
* Nkarta press release [https://seekingalpha.com/pr/20512111-nkarta-reports-first-quarter-2026-financial-results-and-corporate-highlights] (NKTX [https://seekingalpha.com/symbol/NKTX]): Q1 GAAP EPS of -$0.37 in-line. * Nkarta had cash, cas…
Nkarta NKTX shares surged 15.7% on Thursday, reflecting strong investor optimism following a meaningful regulatory update tied to its lead autoimmune program, NKX019, an investigational CAR-NK cell therapy. The rally was observed after NKT…
* Nkarta (NKTX [https://seekingalpha.com/symbol/NKTX]) filed a $350M mixed-securities shelf offering with the SEC [https://seekingalpha.com/filing/222268734] to raise funds and plans to sell up to $100M in common stock (par value $0.0001)…
The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NHL, ALL, NMOSD, IgG4-RD, SLE, multiple sclerosis, and other relate…
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced i…
ImmunityBio(NASDAQ:IBRX), which develops immunotherapies for cancers and infectious diseases, closed Wednesday at $6.92, up 6.79%. The stock moved higher as short-sellers considered what to do after the company’s share price tripled in jus…
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced i…
Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B-cell depletion in pati…
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the follo…
The glomerulonephritis market is witnessing steady growth driven by the increasing prevalence of chronic kidney diseases and improved diagnostic capabilities. Additionally, ongoing clinical trial activities and the launch of emerging thera…
SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it…
In trading on Thursday, shares of Bank OZK (Symbol: OZK) crossed below their 200 day moving average of $47.57, changing hands as low as $46.95 per share. Bank OZK shares are currently trading off about 6.9% on the day. The chart below show…
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the foll…
Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN…
SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the H.C.…
(RTTNews) - Nkarta, Inc. (NKTX), a clinical-stage biopharmaceutical company, on Friday announced that Chief Medical Officer David Shook will be stepping down and Shawn Rose will take over as CMO and Head of Research and Development, effect…
SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced th…
Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropat…
SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor…
Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune indications expected in second half…
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor c…
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. The most oversold stocks in the health care sector present an opport…
For investors looking to maximize profits, marking the appropriate cheap stocks is essential. Here, the focus is on three exceptional businesses, each with solid arguments for being included in a sharp investment plan. For example, these b…
Three equities stand out among the plethora of alternatives as possible Wall Street game-changers. Each represents a distinct industry: energy, cannabis and biotechnology. The first company is a shining light in biotechnology due to its in…
In the stock markets, where giants often steal the investment spotlight, hidden gems await discovery. Beyond the limelight lay under-the-radar stocks for 300% growth, teeming with potential and ready to soar to heights unimaginable to many…
The biotech sector is one of my favorite sectors since it is not only constantly growing and with companies that are always doing wonderful research, products, and solutions, but it is also a sector that is constantly innovating and contri…
Key Insights Given the large stake in the stock by institutions, Nkarta's stock price might be vulnerable to their trading decisions A total of 7 investors have a majority stake in the company with 55% ownership Using data from analyst for…
Nkarta, Inc. SOUTH SAN FRANCISCO, Calif., Dec. 09, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced a poster presenta…
Nkarta, Inc. (NKTX) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting s…
Overview of the Recent Transaction T. Rowe Price Investment Management, Inc. (Trades, Portfolio), a renowned investment firm, has recently adjusted its investment in Nkarta Inc (NASDAQ:NKTX), a biopharmaceutical company. On October 31, 202…
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Nkarta, Inc. (NASDAQ: NKTX) (“Nkarta”) on behalf of the company’s investors. Since June 2023, shares of Nkarta’s common stock have declined…
FDA clearance of IND for NKX019 in lupus nephritis expands pipeline into autoimmune diseaseNKX019, a first-in-class engineered NK cell therapy, has disease-modifying potential in autoimmune disease while maintaining NK-driven safety profil…
Nkarta, Inc. FDA clearance of IND for NKX019 in lupus nephritis expands pipeline into autoimmune disease NKX019, a first-in-class engineered NK cell therapy, has disease-modifying potential in autoimmune disease while maintaining NK-driven…